Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Jazz Pharmaceuticals revenue
Jazz Pharmaceuticals's revenue is $4.1 billion.
What is Jazz Pharmaceuticals's revenue?
- Jazz Pharmaceuticals annual revenue for 2024 was 4.1B, 6.12% growth from 2023.
- Jazz Pharmaceuticals's revenue growth from 2006 to 2024 is 8,971.14%.
- Jazz Pharmaceuticals has 1,210 employees, and the revenue per employee ratio is $3,362,768.
- Jazz Pharmaceuticals's peak quarterly revenue was $1.1B in 2024(q4).
- Jazz Pharmaceuticals peak revenue was $4.1B in 2024.
- Jazz Pharmaceuticals annual revenue for 2023 was 3.8B, 4.78% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Jazz Pharmaceuticals historical revenue
Jazz Pharmaceuticals's peak revenue was $4.1B in 2024. The peak quarterly revenue was $1.1B in 2024(q4).
Jazz Pharmaceuticals's revenue increased from $44.9m in 2006 to $4.1B currently. That's a 8,971.14% change in annual revenue.
Jazz Pharmaceuticals annual revenue
Jazz Pharmaceuticals annual revenue over time
| Fiscal year / year | Jazz Pharmaceuticals revenue |
|---|---|
| 2009 | $128.4M |
| 2010 | $173.8M |
| 2011 | $272.3M |
| 2012 | $586.0M |
| 2013 | $872.4M |
| 2014 | $1.2B |
| 2015 | $1.3B |
| 2016 | $1.5B |
| 2017 | $1.6B |
| 2018 | $1.9B |
| 2019 | $2.2B |
| 2020 | $2.4B |
| 2021 | $3.1B |
| 2022 | $3.7B |
| 2023 | $3.8B |
| 2024 | $4.1B |
How accurately did Jazz Pharmaceuticals' revenue projections match actual performance?
Jazz Pharmaceuticals annual growth
Jazz Pharmaceuticals saw the greatest revenue growth in 2012, when revenue increased by 115.21%.
Jazz Pharmaceuticals had the lowest revenue growth in 2008, when revenue changed by 3.39%.
Jazz Pharmaceuticals annual growth rate over time
| Year | Jazz Pharmaceuticals growth |
|---|---|
| 2009 | 90%↑ |
| 2010 | 35%↑ |
| 2011 | 57%↑ |
| 2012 | 115%↑ |
| 2013 | 49%↑ |
| 2014 | 34%↑ |
| 2015 | 13%↑ |
| 2016 | 12%↑ |
| 2017 | 9%↑ |
| 2018 | 17%↑ |
| 2019 | 14%↑ |
| 2020 | 9%↑ |
| 2021 | 31%↑ |
| 2022 | 18%↑ |
| 2023 | 5%↑ |
| 2024 | 6%↑ |
Jazz Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Jazz Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $22.1M | $37.3M | $30.8M | $38.3M |
| 2010 | $35.2M | $40.5M | $44.8M | $53.4M |
| 2011 | $50.9M | $64.6M | $73.3M | $83.5M |
| 2012 | $102.5M | $124.2M | $175.5M | $183.7M |
| 2013 | $196.2M | $208.3M | $232.2M | $235.8M |
| 2014 | $246.9M | $291.2M | $306.6M | $328.1M |
| 2015 | $309.3M | $333.7M | $340.9M | $340.9M |
| 2016 | $336.0M | $381.2M | $374.2M | $396.6M |
| 2017 | $376.1M | $394.4M | $411.9M | $436.4M |
| 2018 | $444.6M | $500.5M | $469.4M | $476.5M |
| 2019 | $508.2M | $534.1M | $537.7M | $581.7M |
| 2020 | $534.7M | $562.4M | $600.9M | $665.5M |
| 2021 | $607.6M | $751.8M | $838.1M | $896.7M |
| 2022 | $813.7M | $932.9M | $940.7M | $972.1M |
| 2023 | $892.8M | $957.3M | $972.1M | $1.0B |
| 2024 | $902.0M | $1.0B | $1.1B | $1.1B |
Jazz Pharmaceuticals jobs nearby
Do you work at Jazz Pharmaceuticals?
Did Jazz Pharmaceuticals meet its revenue projections?
Jazz Pharmaceuticals financial information
| CEO | Bruce C. Cozadd |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 1,210 |
| Date Founded | 2005 |
| Headquarters | Palo Alto, California |
| Number of Locations | 3 |
| Revenue | $4.1B |
| Net Income | -$204,218,000 |
| Gross Proft | $3.6B (2024) |
| EBITDA | $1.3B (2024) |
| PE Ratio | 15.18 |
| Tax Rate | -0.2% |
| Market Capitalization | $8.5B |
| Total Assets | $10,835,255,000 |
| Ticker | JAZZ |
Jazz Pharmaceuticals jobs you might like
Jazz Pharmaceuticals financing
Jazz Pharmaceuticals received early financing of $7.1M on 2003-09-15.
| Series | Round size | Date |
|---|---|---|
| Series A | $7.1M | 09/2003 |
| Series B | $250M | 03/2004 |
| Post Ipo Equity | $75M | 05/2008 |
| Post Ipo Equity | $7.0M | 07/2009 |
| Post Ipo Debt | $120M | 12/2009 |
| Post Ipo Debt | $1.5B | 04/2021 |
Jazz Pharmaceuticals investors
| Investors | Security type |
|---|---|
| BPOC | Series B |
| WAUD CAPITAL PARTNERS | Series B |
| Versant Ventures | Series B |
| Adams Street Partners | Series B |
| Lehman Brothers Inc | Series B |
| Prospect Venture Partners | Series B |
| KKR & Co. Inc. | Series B |
| Thoma Cressey Equity Partners | Series B |
| EGS Healthcare Capital Partners | Series B |
| Golden Gate Capital | Series B |
| Kingsbridge Capital Ltd | Post Ipo Equity |
| Longitude Capital | Post Ipo Equity |
Jazz Pharmaceuticals competitors
Jazz Pharmaceuticals's top competitor, Endo Pharmaceuticals Inc, earned an annual revenue of $2.6B.
Jazz Pharmaceuticals's smallest competitor is Topix Pharmaceuticals with revenue of $11.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Santarus | - | $218.0M | 290 | - |
| Eagle Pharmaceuticals | - | $316.6M | 96 | - |
| Intercept Pharmaceuticals | - | $285.7M | 437 | - |
| Eton Pharmaceuticals | - | $959,000 | 10 | - |
| Aclaris Therapeutics | - | $18.7M | 60 | - |
| Cerimon Pharmaceuticals | - | $760,000 | 4 | - |
| Dova Pharmaceuticals | - | $10.4M | 115 | - |
| AltaThera Pharmaceuticals | - | $590,000 | 10 | - |
| Evoke Pharma | - | $1.0M | 6 | - |
| Avanir Pharmaceuticals | - | $115.0M | 200 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Jazz Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Jazz Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Jazz Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Jazz Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Jazz Pharmaceuticals. The data presented on this page does not represent the view of Jazz Pharmaceuticals and its employees or that of Zippia.
Jazz Pharmaceuticals may also be known as or be related to JAZZ PHARMACEUTICALS INC, Jazz Pharmaceuticals, Jazz Pharmaceuticals Inc and Jazz Pharmaceuticals plc.